Market research
6190.TSE PhoenixBio Co., Ltd
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 10.4
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.36
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3803010002
- Market cap
- 1B
- P/E ratio
- 10.4
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.36
About
About PhoenixBio Co., Ltd
PhoenixBio Co., Ltd. provides contract testing services for medical product development in Japan, the United States, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver used in drug development experiments; and PXB-cells, human hepatocytes for in vitro studies and experiments, as well as HBV study services. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 6190.TSE discussion.
5 years, 5 months ago
PhoenixBio Co., Ltd is currently in a long term uptrend where the price is trading 2.7% above its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
PhoenixBio Co., Ltd's total revenue sank by 35.9% to $200M since the same quarter in the previous year.
Its net income has dropped by 185.1% to $-80M since the same quarter in the previous year.
Based on the above factors, PhoenixBio Co., Ltd gets an overall score of 2/5.